On Wednesday, the Food and Drug Administration (FDA) approved first two drugs that can slow the progression of a fatal lung disease. This approval could open not only a new era for patients but also a new chapter in the controversy over high drug prices.
The two drugs are: Roche's Esbriet and Boehringer Ingelheim's Ofev. Both these drugs are developed to treat idiopathic pulmonary fibrosis, which is a condition of scarring of the lungs. It affects roughly 100,000 Americans and kills many of them three to five years after diagnosis.